Pre-made Inotuzumab benchmark antibody ( Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-275

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-275 Category Tag

Product Details

Pre-Made Inotuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Products Name (INN Index)

Pre-Made Inotuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody

INN Name

Inotuzumab

Target

CD22

Format

Whole mAb ADC

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2004

Companies

Alliance for Clinical Trials in Oncology,Cancer Research UK,Case Comprehensive Cancer Center,Children's Oncology Group,Erasmus MC,M. D. Anderson Cancer Center,National Cancer Institute (USA),Pfizer,S

Conditions Approved

Precursor cell lymphoblastic leukaemia-lymphoma

Conditions Active

Precursor B-cell lymphoblastic leukaemia-lymphoma,Chronic myeloid leukaemia

Conditions Discontinued

Acute biphenotypic leukaemia,Burkitt's lymphoma,Diffuse large B cell lymphoma,Non-Hodgkin's lymphoma

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CD22

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide